News | News By Subject | News by Disease News By Date | Search News

Graft vs. Host Disease News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AbbVie (ABBV) Nabs Breakthrough Tag for Ibrutinib to Treat Chronic Graft-Versus-Host-Disease     6/29/2016
FDA Bestows Incyte (INCY)'s Ruxolitinib with Breakthrough Tag for Graft-Versus-Host Disease     6/23/2016
Chimerix (CMRX) Shares Plunge After Brincidofovir Fails in Phase III Trial     12/29/2015
Fate Therapeutics (FATE) Discontinues Development of ProHema in Patients Undergoing Cord Blood HCT     12/7/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Rigel Pharmaceuticals, Inc. (RIGL) Experimental Eye Drug R348 Fails Mid-Stage Study     8/14/2014
DOR BioPharma, Inc. (DORB) Receives Guidance From FDA on Proposed Confirmatory Phase 3 Clinical Trial Design of orBec(R) in GI GVHD     11/10/2008
DOR BioPharma, Inc. (DORB) Has Voluntarily Withdrawn European Marketing Authorization Application (MAA) For Orbec(R) For The Treatment Of Gastrointestinal Graft-Versus-Host Disease (GI GVHD)     5/22/2008
Osiris Therapeutics, Inc. (OSIR) (Jobs) Receives FDA Fast Track Status for Prochymal(TM) as First-Line Treatment for Acute GvHD     12/10/2007
FDA Advisory Panel Advises Against DOR BioPharma, Inc. (DORB)'s orBec(R) Approval     5/10/2007
FDA Advisory Committee To Review DOR BioPharma, Inc. (DORB)'s orBec(R) For The Treatment Of GI GVHD     1/31/2007
Pharming Group (PHGUF.PK)'s Lead Drug Receives Orphan Drug Designations From The FDA; Shares Soar     6/14/2006
Osiris Therapeutics, Inc. First To Announce FDA Fast Track Designation For A Stem Cell Product; Decision Seen As A Positive Sign For Both Osiris And The Emerging Stem Cell Industry     1/31/2005

News from Around the Web
Treatment May Limit Graft-Versus-Host Disease, Universitatsklinikum Freiburg Study     8/20/2009
Embryonic Stem Cells Reduce Transplantation Rejection, University of Iowa Study     9/16/2008
Bone Marrow Transplants: Cancer Drug Shows Promise Against Graft Vs. Host Disease in University of Michigan Study     7/17/2008
Immune Molecule that Plays a Powerful Role in Avoiding Organ Rejection Identified in Medical College of Georgia Study     6/20/2008
Mesenchymal Stem Cells Can Suppress Life-Threatening Immune Reaction, Karolinska Institute and Karolinska University Hospital Study     5/14/2008
Uncooked Fish Linked with Liver Cancer in Asia -- Graft-Versus-Host Disease     7/10/2007
Study Shows Rituximab Effective In Treating Chronic Graft-Versus-Host Disease     3/24/2006
New Tissue "Grown Within Minutes"     10/17/2005
Transplant Rejection Averted By Simple Light Exposure In Stanford Animal Study     5/7/2004
Level Of Immune Cells Predict Chances Against Leukemia     3/19/2004
Drugs Limit Deadly Side Effects Of Graft-Versus-Host Disease     3/1/2004

Press Releases
CytoDyn (CYDY) Treats First Patient With PRO 140 In Phase II Trial For Graft Versus Host Disease     5/17/2017
Janssen R&D Release: U.S. FDA Accepts For Review The Application Of Ibrutinib (IMBRUVICA) For Chronic Graft-Versus-Host-Disease (Cgvhd) After Failure Of One Or More Lines Of Systemic Therapy     4/4/2017
AbbVie (ABBV) Announces Ibrutinib (IMBRUVICA) Supplemental New Drug Application For Previously Treated Chronic Graft-Versus-Host-Disease (Cgvhd) Accepted For Review By U.S. FDA     4/4/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD)     3/3/2017
Kalytera Therapeutics Announces Encouraging Results Of A Phase IIa Clinical Study For The Treatment Of Acute Graft Versus Host Disease     2/22/2017
Kalytera Therapeutics To Announce Phase IIa Clinical Study Results Investigating CBD For The Treatment Of Acute Graft Versus Host Disease     2/17/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease     1/23/2017
Fate Therapeutics (FATE) Announces First Patient Treated In Protmune PROTECT Clinical Trial For The Prevention Of Graft-Versus-Host Disease     1/5/2017
Mesoblast (MSB.AX) And Mallinckrodt (MNK) Enter Into Equity Purchase Agreement To Exclusively Negotiate Development And Commercialization Of Mesoblast's Cell Therapy Products For Chronic Low Back Pain And Acute Graft Versus Host Disease     12/27/2016
Janssen R&D Release: Late-breaking Phase 2 Ibrutinib Study In Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete Or Partial Response In Up To Two-Thirds Of Steroid Dependent Or Refractory Patients     12/6/2016
AbbVie (ABBV) Release: Late-Breaking Ibrutinib (IMBRUVICA) Data Show Complete Or Partial Response In Two-Thirds Of Patients With Chronic Graft-Versus-Host-Disease, A Frequent And Potentially Life-Threatening Complication Of Stem Cell Transplant     12/6/2016
Kamada Ltd. (KMDA) Announces Plan For Phase II/III Clinical Trial With Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease     11/2/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease     9/15/2016
Alexion (ALXN) Release: European Commission (EC) Grants Orphan Drug Designation To ALXN1007 For The Treatment Of Patients With Graft-Versus-Host Disease (GVHD)     8/30/2016
FDA Grants Orphan-Drug Designation For Regenicin, Inc.'s NovaDerm Cultured Skin Substitute     8/30/2016

//-->